Charles River lays out $293M to snap up viral vector specialist Vigene, its 2nd M&A deal this year
A few short months after Charles River Laboratories acquired Cognate BioServices, the company is folding yet another CDMO into its cell and gene network, signing more than $ 1 billion in M&A outlays so far this year. Charles River Laboratories has inked a deal to pay $ 292.5 million in cash for gene therapy CDMO Vigene Biosciences,… Read More: Charles River lays out $293M to snap up viral vector… »